Glandokort

Glandokort, marketed under the product code A-17, is one of a family of tissue-specific "peptide bioregulators" developed by Prof. Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, an institute with roots in Soviet-era, military-funded aging and stress-resilience research beginning in the 1970s. At Verified Peptides, we think it is important to be precise about what Glandokort actually is before discussing its research profile: it belongs to Khavinson's "cytomax" product line, meaning it is a natural, multi-component peptide complex extracted from young calf or pig adrenal cortex tissue, not a single, defined amino acid sequence synthesized in a laboratory.

This distinguishes Glandokort from the majority of peptides in this catalog, including several other Khavinson-associated names built on this site (such as Vilon and Thymogen), which belong to a separate "cytogen" product line — short, single-sequence synthetic peptides (typically 2-4 amino acids) engineered to reproduce what Khavinson's group identified as the active fragment of the corresponding natural tissue complex. Glandokort has no single reported molecular formula, molecular weight, or CAS number, because it is, by design, a heterogeneous mixture rather than one compound — a genuinely important distinction for researchers evaluating it alongside single-sequence peptides.

Commercially, Glandokort is formulated and sold as an oral capsule supplement (commonly 10 mg of peptide complex per capsule), positioned as a parapharmaceutical or dietary supplement rather than an approved pharmaceutical drug in any jurisdiction, including Russia, the United States, or the European Union.

At Verified Peptides, we want to be unusually direct about the evidence quality for Glandokort, because it differs meaningfully from most other compounds in our catalog. The closest available indexed, peer-reviewed reference is a broader review by Khavinson and Kuznik, "Peptide bioregulators: the new class of geroprotectors" (PMID 23734519), which summarizes decades of the institute's own experimental and animal research across its entire bioregulator product line, including organ-specific cytomax and cytogen preparations. This review is a genuine PubMed-indexed publication, but it is authored by the same research group that developed and commercially sells these products, and it summarizes the group's own body of work rather than presenting independent third-party validation — an important conflict-of-interest consideration for researchers weighing its conclusions.

The only Glandokort-specific human data we could locate is a small clinical study conducted at the Medical Center of the Saint Petersburg Institute of Bioregulation and Gerontology — the same institute that developed and sells the product — from April to November 2011. The study enrolled 36 patients (25 men, 11 women, ages 37-62) with chronic adrenal cortex insufficiency or prolonged occupational and psycho-emotional stress, treated with 1 capsule twice daily for 30 days alongside standard adaptogen therapy, compared against a 26-patient control group receiving conventional therapy alone. Researchers measured aldosterone, 17-ketosteroids, cortisol, and ACTH via radioimmunological and biochemical methods, reporting that Glandokort treatment shifted aldosterone and 17-ketosteroid levels toward normal ranges and normalized cortisol and ACTH in stress-exposed patients, alongside reported improvements in subjective physical and mental performance, mood, and sleep, with no adverse effects or dependence noted.

We want to be equally direct about this study's real limitations: we have not located a peer-reviewed journal publication of this specific trial, meaning it is described only in institute and vendor-facing materials rather than in the independently-reviewed scientific literature; no randomization or blinding methodology is described; the sample size is small; and it was conducted, analyzed, and reported entirely by the same institution with a direct commercial interest in a positive result. None of this means the reported findings are false, but it does mean this evidence sits well below the bar of an independent, peer-reviewed, randomized controlled trial, and researchers should treat it accordingly — as preliminary, institute-internal data rather than externally validated clinical evidence.

No FDA, EMA, or other Western regulatory body has evaluated or approved Glandokort for any indication, and we are not aware of any independent replication of its specific adrenal-function findings by researchers outside the originating institute. A direct search of PubMed for "Glandokort" by name returns no dedicated, indexed research record under that specific product name — the compound's presence in the indexed literature exists only indirectly, folded into the broader Khavinson bioregulator review cited above, rather than as its own standalone, independently indexed study. Researchers should factor this absence into how much evidentiary weight they place on Glandokort specifically, as distinct from the wider bioregulator research program it belongs to. At Verified Peptides, we sell research-grade Glandokort strictly for laboratory research purposes, and we encourage researchers to treat its evidence base as preliminary and institute-internal rather than as an independently established clinical finding.

The distinction between Khavinson's "cytomax" and "cytogen" product lines is one of the more consistently misunderstood aspects of this research program, and it matters directly for how researchers should interpret Glandokort. Cytomaxes, including Glandokort, are natural multi-peptide complexes extracted from young calf or pig tissue, while cytogens are synthetic single-sequence peptides representing what the institute's researchers identified as each cytomax's most active fragment. According to the institute's own comparative claims, cytomaxes are reported to produce stronger and longer-lasting effects (with claimed aftereffects persisting 6-12 months following a course) compared to the faster-onset, shorter-duration cytogens — claims that, like much of this compound's evidence base, originate from the developing institute rather than independent researchers.

The "A-17" product code assigned to Glandokort reflects the institute's internal numbering system for its bioregulator product line, which spans organ-specific preparations for the pineal gland, thymus, brain, heart, blood vessels, liver, kidneys, eyes, joints, bones, lungs, stomach, bladder, prostate, ovaries, testes, adrenal glands, thyroid, parathyroid, muscles, and bone marrow — a genuinely large research program built around the same tissue-selective peptide-gene hypothesis across dozens of organ systems.

The broader Khavinson peptide bioregulator research program is reported to trace back to Soviet military-funded research beginning in the 1970s, originally investigating peptide extracts for stress resilience and functional recovery in military and high-performance occupational contexts (submariners, pilots, and similar populations under sustained physiological stress), before the research program transitioned into the civilian aging and longevity research it is publicly associated with today.

Because Glandokort is a heterogeneous natural extract rather than a single synthesized compound, it cannot be quantified or verified the same way a single-sequence peptide can — there is no single molecular weight or defined sequence against which a batch's identity can be confirmed via mass spectrometry. This is a structural limitation of tissue-extract complexes generally, not specific to Glandokort, but it is an important practical consideration for any research context requiring precise compound identity verification.

At Verified Peptides, we require documentation of sourcing standards and manufacturing controls for the animal tissue material used to produce research-grade Glandokort, since it is derived from adrenal cortex tissue rather than synthesized from individual amino acids. Because Glandokort is a heterogeneous natural complex rather than a single molecular entity, standard single-compound purity metrics (such as HPLC purity percentage against one target molecule) do not directly apply the way they do for a synthesized peptide — verification instead focuses on confirming consistent extraction and processing methodology, microbial and endotoxin testing, and batch-to-batch consistency in the overall peptide-complex preparation.

We source exclusively from manufacturers operating under quality-controlled manufacturing systems, and we recommend researchers request whatever batch documentation is available and treat compositional consistency claims with appropriate caution given the inherent difficulty of fully characterizing a heterogeneous natural peptide mixture compared to a single defined-sequence compound.

Researchers evaluating Glandokort for any experimental protocol should be aware that batch-to-batch compositional variability is a more meaningful concern for a natural tissue-extract complex than it is for a synthesized single-sequence peptide, and should design experiments with this variability in mind.

Glandokort is typically supplied and studied as a lyophilized (freeze-dried) peptide complex in oral capsule form, and should be stored in a cool, dry place protected from light and moisture, consistent with standard storage guidance for lyophilized natural peptide preparations. At Verified Peptides, we ship material with packaging appropriate to preserve stability in transit.

Because Glandokort is a heterogeneous natural extract rather than a single molecular species, its overall stability profile reflects the combined behavior of its constituent peptides rather than a single, well-characterized degradation pathway. Researchers should follow the specific storage guidance provided with each lot's documentation and avoid exposure to excessive heat, humidity, or direct light, which can degrade natural peptide preparations similarly to synthetic ones.

Given the more limited analytical characterization available for a multi-peptide complex compared to a single-sequence compound, researchers relying on long-term storage stability data for Glandokort specifically should treat general peptide-storage principles as a reasonable but not compound-specifically validated guide.